Partner Releases News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2)
NEW YORK CITY (dpa-AFX) - Today s Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer s Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid s investigational medicine Soticlestat.
Read on.
1.KemPharm Scores FDA Nod For ADHD Drug
KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FDA approval of AZSTARYS (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older. ....

Takeda Shonan , Johnson Concerta , Ovid Soticlestat , Vir Biotechnology Inc , Magenta Therapeutics Inc , Corium Inc , Ocugen Inc , National Institutes Of Health Accelerating , Pfizer Inc , Kempharm Inc , Ovid Therapeutics Inc , Guardion Health Sciences Inc , Sana Biotechnology Inc , United Therapeutics Corporation , Lucira Health Inc , Asensus Surgical Inc , Medicinova Inc , Daily Dose , United Therapeutics , Vir Biotechnology , Pharm Scores , Noven Pharmaceutical , Gurnet Point Capital , Nova Quits , Respiratory Syncytial , Partner Releases ,